Mepolizumab for the treatment of refractory chronic cough in patients with eosinophilic airways disease (MUCOSA): a randomized, double-blind, parallel-group, placebo-controlled trial.

OBJECTIVE: Patients presenting with chronic cough often have eosinophilic airways disease that remains refractory despite inhaled or oral corticosteroids. Studies in asthma patients have shown that eosinophils co-localize with airway sensory nerves, and after allergen challenge, are associated with neuronal sensitivity. We evaluated whether mepolizumab, a monoclonal antibody targeting interleukin-5, reduces cough in patients with eosinophilic …